Key Performance
More- Earnings Score: N/A
- Momentum Score: 15
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
A class action lawsuit has been filed against Immutep Limited alleging that company defendants made materially false and misleading statements regarding the TACTI-004 trial's status and prospects. The complaint claims defendants concealed negative clinical data and misrepresented the trial's operational progress and interim futility analysis timing. Investors who purchased Immutep securities between March 24, 2025 and March 12, 2026 are eligible to join the case, with a lead plaintiff deadline of July 6, 2026.
06/03/2026, 12:00 PM • GlobeNewswire
Rosen Law Firm is soliciting investors who purchased securities of Immutep Ltd., POET Technologies Inc., and DNOW Inc. to join class action lawsuits. The Immutep case alleges the company made false statements about its TACTI-004 trial prospects, concealing material risks of study failure. The deadline to serve as lead plaintiff in the Immutep case is July 6, 2026.
06/02/2026, 6:41 PM • GlobeNewswire
Rosen Law Firm has filed securities class action lawsuits against POET Technologies, Immutep Ltd., and DNOW Inc., alleging material misstatements and omissions. POET Technologies is accused of misrepresenting its tax status as a PFIC and having an executive violate non-disclosure agreements. Investors with losses exceeding $100,000 are encouraged to join the class actions before the June 29, 2026 lead plaintiff deadline.
06/02/2026, 6:09 PM • GlobeNewswire
A securities class action lawsuit has been filed against Immutep Ltd. (NASDAQ: IMMP) for allegedly making false and misleading statements about the TACTI004 trial. The company reportedly concealed negative information about the trial's prospects while publicly stating it was on track, despite internal data suggesting increased risk of failure. Investors who purchased ADRs between March 24, 2025 and March 12, 2026 may be eligible for compensation, with a lead plaintiff deadline of July 6, 2026.
05/30/2026, 7:13 AM • GlobeNewswire
A securities class action lawsuit has been filed against Immutep Ltd. (NASDAQ: IMMP) alleging that defendants made false and misleading statements regarding the TACTI004 trial. The company allegedly concealed negative information about the trial's prospects while publicly stating it was on track, despite internal data suggesting increased risk of failure. Investors who purchased ADRs between March 24, 2025 and March 12, 2026 may be eligible for compensation. The lead plaintiff deadline is July 6, 2026.
05/27/2026, 10:28 PM • GlobeNewswire
Rosen Law Firm is soliciting investors for multiple securities class action lawsuits. The primary case involves Graphic Packaging Holding Company (GPK), where investors who purchased securities between February 4, 2025 and February 2, 2026 may be eligible for compensation. The lawsuit alleges that Graphic Packaging made false statements regarding inventory management, demand, costs, and financial guidance. The lead plaintiff deadline is July 6, 2026. Additional class actions are mentioned for Upstart Holdings (UPST) and Immutep Ltd. (IMMP).
05/27/2026, 10:24 PM • GlobeNewswire
A class action lawsuit has been filed against Immutep Limited alleging that company defendants made materially false and misleading statements regarding the TACTI-004 trial's status and prospects. The complaint claims defendants concealed negative clinical data while misrepresenting the trial's operational progress and efficacy prospects. Investors who purchased Immutep securities between March 24, 2025 and March 12, 2026 may be eligible to join the case, with a lead plaintiff deadline of July 6, 2026.
05/25/2026, 12:00 PM • GlobeNewswire
A securities class action lawsuit has been filed against Immutep Ltd. (IMMP) for allegedly making false and misleading statements about the TACTI004 trial. The company reportedly concealed negative information about the trial's prospects while publicly stating it was on track, despite internal data suggesting increased risk of failure. Investors who purchased ADRs between March 24, 2025 and March 12, 2026 may be eligible for compensation, with a lead plaintiff deadline of July 6, 2026.
05/24/2026, 10:45 PM • GlobeNewswire
A class action lawsuit has been filed against Immutep Limited (NASDAQ: IMMP) alleging that company defendants made materially false and misleading statements regarding the TACTI-004 trial's status and prospects. The complaint claims defendants concealed negative clinical data while misrepresenting the trial's operational progress and efficacy prospects. Investors who purchased Immutep securities between March 24, 2025 and March 12, 2026 may be eligible to join the case, with a lead plaintiff deadline of July 6, 2026.
05/21/2026, 12:00 PM • GlobeNewswire
A shareholder class action lawsuit has been filed against Immutep Limited alleging false and misleading statements regarding the status and prospects of its TACTI-004 trial. Investors who purchased shares between March 24, 2025 and March 12, 2026 and experienced losses are encouraged to contact the law firm. The deadline to be appointed lead plaintiff is July 6, 2026.
05/20/2026, 8:00 AM • GlobeNewswire
A class action lawsuit has been filed against Immutep Limited (NASDAQ: IMMP) alleging that company defendants made materially false and misleading statements regarding the TACTI-004 trial's status and prospects. The complaint claims defendants concealed negative clinical data while misrepresenting the trial's operational progress and safety outcomes. Investors who purchased Immutep securities between March 24, 2025 and March 12, 2026 are eligible to join the case, with a lead plaintiff deadline of July 6, 2026.
05/18/2026, 12:00 PM • GlobeNewswire
A class action lawsuit has been filed against Immutep Limited (IMMP) for allegedly misleading investors about the viability of its TACTI-004 drug trial. The company claimed strong progress in January 2026, but in March 2026 announced the trial would be discontinued for futility, causing the stock to plummet 83% from $2.76 to $0.48 per share. The lead plaintiff deadline is July 6, 2026.
05/14/2026, 5:37 PM • GlobeNewswire
A class action lawsuit has been filed against Immutep Limited (NASDAQ: IMMP) alleging that company defendants made materially false and misleading statements regarding the TACTI-004 trial's status and prospects. The complaint claims defendants concealed negative clinical data while misrepresenting the trial's operational progress and efficacy prospects. Investors who purchased Immutep securities between March 24, 2025 and March 12, 2026 are eligible to join the case, with a lead plaintiff deadline of July 6, 2026.
05/14/2026, 12:00 PM • GlobeNewswire
A class action lawsuit has been filed against Immutep Limited on behalf of shareholders who purchased ADRs between March 24, 2025 and March 12, 2026. The lawsuit alleges that defendants concealed material information about the TACTI-004 trial, misrepresenting its status and prospects despite internal data indicating increased risk of failure to meet primary efficacy and safety endpoints. Shareholders have until July 6, 2026 to serve as lead plaintiff.
05/14/2026, 10:55 AM • GlobeNewswire
Rosen Law Firm is reminding investors in Gossamer Bio, ImmunityBio, and Immutep Ltd. about upcoming deadlines to join securities class action lawsuits. The lawsuits allege that defendants made false and misleading statements to investors, with Gossamer Bio specifically accused of concealing material adverse facts concerning its Phase 3 PROSERA study design. Investors who purchased securities during specified class periods may be eligible for compensation.
05/13/2026, 2:47 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/02/2026
Company Profile
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.